Cancer drug sitravatinib tested for Long-Term use in advanced tumors
Disease control
Completed
This study followed 52 people with advanced or metastatic solid tumors who were already benefiting from sitravatinib treatment in an earlier study. The main goal was to track side effects over time. Participants continued their current sitravatinib regimen (alone or with other dr…
Phase: PHASE2, PHASE3 • Sponsor: Mirati Therapeutics Inc. • Aim: Disease control
Last updated May 01, 2026 16:00 UTC